Obesity Drug Market: Opportunities and Obstacles

The obesity drug market has grown dramatically in the last few years, especially with the help of social media and influencers. The immense popularity of anti-obesity medications has transformed a health industry development into a cultural phenomenon. While this market has so much opportunity, it also faces supply issues and coverage gaps. Mindy and Jen are joined by Vynamic’s Head of Life Sciences, Karen Baldry, and Head of Health Plans, Saurabh Raman, to talk about the growth and challenges obesity medications present for the health industry.    

Podcast Tags: healthcare, obesity, weight loss, diabetes, health services, health plans, life sciences  

Source Links: 

• What Is Ozempic and Why Is It Getting So Much Attention? 
• We Know Where New Weight Loss Drugs Came From, but Not Why They Work 
• What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know 
• Supply Updates about Wegovy
• The increase in appetite for obesity drugs 
• Demand for GLP-1 drugs is growing. Here’s why payers are hesitant to cover them for weight loss 

• More than 4,000 ads for Ozempic-style drugs found running on Instagram and Facebook  
• Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs 
• Medicare is barred from paying for weight-loss drugs like Wegovy. Lawmakers just took the first step to change that 
• Cost isn’t the only reason Medicare doesn’t cover Wegovy
• New marketing push by Ozempic and others sparks body-positive backlash 
• What You Need to Know About Compounded Versions of Popular Weight Loss Drugs 
• Novo antes up $16.5B to poach CDMO giant Catalent amid Wegovy surge  
• Wegovy, other GLP-1s could lower heart disease: Study  
• Novo kidney trial finds Ozempic cuts cardiac deaths in diabetics  
• How Ozempic and Weight Loss Drugs Are Reshaping Denmark’s Economy  
• Novo Nordisk’s Wegovy bonanza looms large in Denmark  
• Big pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billion  
• Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect  
• Ozempic vs Wegovy 
• Obesity drug boom pushes Novo Nordisk shares to record high 
• Popular use of obesity drugs like Ozempic could change consumer habits 

Panel – Jen Burke, Mindy McGrath, Karen Baldry, Saurabh Raman 

Research & Production – Adrea Cope, Everly Petruzzelli 

Recording & Editing – Mike Liberto, Rachel Skonecki 

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.